Molecular Partners is a clinical-stage biotechnology company developing DARPin (Designed Ankyrin Repeat Protein) therapeutics, a novel class of engineered protein drugs with properties including high affinity and specificity, small size, and stability that enable multiple therapeutic mechanisms. The company advances a pipeline of oncology-focused candidates including radio-DARPins for targeted radioactive isotope delivery to tumors, multispecific T-cell engagers, and immune cell activators, with programs in clinical development for small-cell lung cancer, neuroendocrine tumors, ovarian cancer, and acute myeloid leukemia. Molecular Partners operates through a combination of internal development of proprietary programs and strategic partnerships with collaborators that advance drug candidates while the company retains commercialization rights, with revenue derived from milestone payments, royalties, and shared development arrangements as its candidates progress toward commercialization.